Forwarded from Yeouido Lab_์ฌ์๋ ํบ์๋ณด๊ธฐ
1๋
๋ค์ ์ค๋์ ๋ดค์ ๋,
์ง๊ธ์ ๋น๊ณ ๋์ด ๊ณต๋์ด์ง๋ง
ํ์ฌ๋ ๋ด๊ฐ ๋ชจ๋ฅด์ง๋ง ๋ด๋ ์๋ ์๊ฒ ๋๋ ์ด์ ๊ฐ ์๋ก ์ ํ์์๊น๋ด ๋ฌด์์.
์ง๊ธ์ ๋น๊ณ ๋์ด ๊ณต๋์ด์ง๋ง
ํ์ฌ๋ ๋ด๊ฐ ๋ชจ๋ฅด์ง๋ง ๋ด๋ ์๋ ์๊ฒ ๋๋ ์ด์ ๊ฐ ์๋ก ์ ํ์์๊น๋ด ๋ฌด์์.
๐คก5๐1
Forwarded from KOREA DAILY INSIGHT - KIS GREG KIM
๋ฉง์ธ๋ผ Series B ์ฐธ์ฌ ๊ธฐ๊ด๋ค์ ํ๋ฆฌํฐ
Metsera raises $215M to accelerate obesity drug plans. Metsera, already a well-funded biotech startup, added another $215 million to its coffers as investors responded to the promise of its obesity drug pipeline.
Wellington Management and Venrock Healthcare Capital Partners led the latest round of financing, the company said Wednesday. New investors included โcrossoverโ investors such as Fidelity Management & Research, Janus Henderson Investors and T. Rowe Price.
The Series B financing brings the total raised for Metsera to more than $500 million. The company officially launched in April after raising $290 million in a financing led by Arch Venture Partners and Population Health Partners.
https://www.biopharmadive.com/news/metsera-obesity-glp-1-series-b-wellington-venrock/732792/
Metsera raises $215M to accelerate obesity drug plans. Metsera, already a well-funded biotech startup, added another $215 million to its coffers as investors responded to the promise of its obesity drug pipeline.
Wellington Management and Venrock Healthcare Capital Partners led the latest round of financing, the company said Wednesday. New investors included โcrossoverโ investors such as Fidelity Management & Research, Janus Henderson Investors and T. Rowe Price.
The Series B financing brings the total raised for Metsera to more than $500 million. The company officially launched in April after raising $290 million in a financing led by Arch Venture Partners and Population Health Partners.
https://www.biopharmadive.com/news/metsera-obesity-glp-1-series-b-wellington-venrock/732792/
Biopharma Dive
Metsera raises $215M to accelerate obesity drug plans
With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of obesity treatments.
๐2โค1๐1
Forwarded from AWAKE - 52์ฃผ ์ ๊ณ ๊ฐ ๋ชจ๋ํฐ๋ง
โ
๊ฒฝ๋จ์คํธ(+16.81%)
* ํค์๋
ํ์คํ,์ฒ ๊ฐ๊ธ์
* ์๊ธฐ์ฃผ์ํํฉ(23.4Q๋ง ๊ธฐ์ค)
- ์ฐ์ ์ฃผ : 0.0%
* ์ฃผ์์งํ
๋ถ์ฑ๋น์จ : 66%
์ ๋ณด์จ : 3,908%
PBR : 0.72๋ฐฐ
*์ต๊ทผ์ค์ (๋งค์ถ/์์ ์ต/์์ต)
2024.3Q 927์ต/ 5์ต/ 2์ต
2024.2Q 1,071์ต/ 26์ต/ 19์ต
2024.1Q 968์ต/ 13์ต/ 14์ต
2023.4Q 910์ต/ 17์ต/ 10์ต
ํ์ฌ์ ๋ณด : https://finance.naver.com/item/main.naver?code=039240
* ํค์๋
ํ์คํ,์ฒ ๊ฐ๊ธ์
* ์๊ธฐ์ฃผ์ํํฉ(23.4Q๋ง ๊ธฐ์ค)
- ์ฐ์ ์ฃผ : 0.0%
* ์ฃผ์์งํ
๋ถ์ฑ๋น์จ : 66%
์ ๋ณด์จ : 3,908%
PBR : 0.72๋ฐฐ
*์ต๊ทผ์ค์ (๋งค์ถ/์์ ์ต/์์ต)
2024.3Q 927์ต/ 5์ต/ 2์ต
2024.2Q 1,071์ต/ 26์ต/ 19์ต
2024.1Q 968์ต/ 13์ต/ 14์ต
2023.4Q 910์ต/ 17์ต/ 10์ต
ํ์ฌ์ ๋ณด : https://finance.naver.com/item/main.naver?code=039240
Naver
๊ฒฝ๋จ์คํธ - Npay ์ฆ๊ถ : Npay ์ฆ๊ถ
๊ด์ฌ์ข
๋ชฉ์ ์ค์๊ฐ ์ฃผ๊ฐ๋ฅผ ๊ฐ์ฅ ๋น ๋ฅด๊ฒ ํ์ธํ๋ ๊ณณ
โค3๐2
โ ๊ทธ๋ ๋ ๋์คํ ํ์ด ์ํ ๊ฑฐ์ผ. ๋ ๋์คํํ ๊ฐ์ฆ์
๐4๐3๐ค3๐3๐ฉ2